State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
Hampel, Harald (Eisai Inc. Neurology Business Group)
Shaw, Leslie M. (Perelman School of Medicine. Department of Pathology and Laboratory Medicine. University of Pennsylvania)
Aisen, Paul (USC Alzheimer's Therapeutic Research Institute)
Chen, Christopher (Memory Aging and Cognition Centre. Departments of Pharmacology and Psychological Medicine. Yong Loo Lin School of Medicine. National University of Singapore)
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau)
Iwatsubo, Takeshi (Department of Neuropathology. Graduate School of Medicine. The University of Tokyo)
Iwata, Atsushi (Tokyo Metropolitan Geriatric Hospital)
Yamada, Masahito (Department of Neurology and Neurobiology of Aging. Kanazawa University Graduate School of Medical Science)
Ikeuchi, Takeshi (Department of Molecular Genetics. Brain Research Institute. Niigata University)
Jia, Jianping (Innovation Center for Neurological Disorders. Department of Neurology. Xuan Wu Hospital. Capital Medical University)
Wang, Huali (Dementia Care and Research Center. Peking University Institute of Mental Health (Sixth Hospital). Beijing Dementia Key Lab. National Clinical Research Center for Mental Disorders)
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC))
Peskind, Elaine (VA Northwest Mental Illness Research. Education and Clinical Center. VA Puget Sound Health Care System. Department of Psychiatry and Behavioral Sciences. University of Washington School of Medicine)
Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital)
Cummings, Jeffrey (Chambers-Grundy Center for Transformative Neuroscience. Department of Brain Health. School of Integrated Health Sciences. University of Nevada Las Vegas (UNLV))
Vergallo, Andrea (Eisai Inc. Neurology Business Group)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. Appropriate incorporation of cerebrospinal fluid biomarker analysis in clinical practice is an essential step toward system readiness for accommodating the demand of AD diagnosis and proper use of DMTs-once they become available. However, the use of lumbar puncture (LP) in individuals with suspected neurodegenerative diseases such as AD is inconsistent, and the perception of its utility and safety differs considerably among medical specialties as well as among regions and countries. This review describes the state-of-the-art evidence concerning the safety profile of LP in older adults, discusses the risk factors for LP-associated adverse events, and provides recommendations and an outlook for optimized use and global implementation of LP in individuals with suspected AD.
Nota:	Altres ajuts: NIH grants (ADNI U19 AG024904); UPenn (ADRC P30 AG010124); MJFox Foundation for Parkinson's Research (MJFF-005441); National Medical Research Council of Singapore; AMED grants (JP20dm0207073, JP20dm0107143); MHLW grants (19192257, 20316440); National Natural Science Foundation of China (81530036); the National Key Scientific Instrument and Equipment Development Project (31627803); Beijing Scholars Program; Beijing Brain Initiative from Beijing Municipal Science & Technology Commission (Z201100005520016, Z201100005520017); Project for Outstanding Doctor with Combined Ability of Western and Chinese Medicine; Beijing Municipal Commission of Health and Family Planning (PXM2019_026283_000003); National Key Research and Development Project grant (2017YFC1311100); Keep Memory Alive (KMA); National Institute of General Medical Sciences grant (P20GM109025); National Institute of Neurological Disorders and Stroke grant (U01NS093334); National Institute on Aging grant (R01AG053798); European Commission (Marie Curie International Training Network, Joint Programme - Neurodegenerative Disease); Health Holland; Dutch Research Council (ZonMw); the Selfridges Group Foundation; Alzheimer Netherlands; Alzheimer Association.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Alzheimer's disease ; Biomarker ; Cerebrospinal fluid ; Diagnosis ; Evidence-based guidelines ; Lumbar puncture ; System readiness
Publicat a:	Alzheimer's & Dementia, Vol. 18 Núm. 1 (january 2022) , p. 159-177, ISSN 1552-5279

DOI: 10.1002/alz.12372
PMID: 34043269

19 p, 1.3 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats